clinical trial · NCT07713732
Phase 1 Safety and Pharmacokinetics Study in Patients With Relapsed/Refractory Solid Tumors
Treeline Biosciences, Inc.·phase1·not yet recruiting·n = 120
Small Cell Lung Cancer ( SCLC )Neuroendocrine CancerMalignant Pleural Mesotheliomas (Mpm)Synovial SarcomasTLN-499Venetoclax
brief summary
The purpose of this first-in-human study is to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of TLN-499 in combination with venetoclax in participants with relapsed/refractory solid tumors.
started
Jul 25, 2026
primary completion
Aug 29, 2030
completion
Aug 29, 2030
last updated
Jul 20, 2026
official title
An Open-Label, Multicenter, Phase 1 Trial to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of TLN-499 in Combination With Venetoclax in Patients With Relapsed/Refractory Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol